Edition:
United Kingdom

Pulmatrix Inc (PULM.OQ)

PULM.OQ on NASDAQ Stock Exchange Global Market

1.45USD
15 Dec 2017
Change (% chg)

$-0.02 (-1.36%)
Prev Close
$1.47
Open
$1.50
Day's High
$1.50
Day's Low
$1.45
Volume
30,008
Avg. Vol
60,509
52-wk High
$6.98
52-wk Low
$0.50

Latest Key Developments (Source: Significant Developments)

Pulmatrix posts Q3 net loss of $0.22 per share
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Pulmatrix Inc :Pulmatrix provides Q3 2017 highlights and Q3 2017 updated financials.Q3 revenue $300,000 versus $100,000.Qtrly ‍net loss per share attributable to common stockholders $0.22​.As of September 30, 2017, Pulmatrix had $6.4 million in cash and cash equivalents, compared to $4.2 million as of December 31, 2016​.  Full Article

FDA grants orphan drug status to Pulmatrix's PUR1900
Wednesday, 17 Aug 2016 

Pulmatrix Inc : Pulmatrix receives orphan drug designation from the FDA for inhaled drug to treat pulmonary fungal infections in cystic fibrosis patients .FDA granted co's request for orphan drug status for drug for treating pulmonary fungal infections in cystic fibrosis patients, named PUR1900.  Full Article

Pulmatrix reports quarterly loss per share $0.62
Thursday, 4 Aug 2016 

Pulmatrix Inc : Quarterly loss per share $0.62 .Revenues for Q2 of 2016 were $0.3 million, compared to $0.2 million for Q2 of 2015.  Full Article

Pulmatrix and Mylan collaborate for pilot pharmacokinetic clinical study
Tuesday, 19 Jul 2016 

Pulmatrix Inc : Pulmatrix led pilot pharmacokinetic clinical study and supportive development work with collaborative support from Mylan . Financial terms of agreement are confidential . Announced positive topline data from a phase 1 pilot pharmacokinetic bioavailability trial of PUR0200 .Mylan has retained an option for PUR0200 EX-U.S. rights based on successful completion of clinical study.  Full Article

Pulmatrix Inc files for mixed shelf of upto $30 mln
Friday, 15 Jul 2016 

Pulmatrix Inc :Pulmatrix Inc files for mixed shelf of upto $30 mln - SEC filing.  Full Article

Capsugel, Pulmatrix enter collaboration to develop, manufacture novel inhaled therapeutics
Tuesday, 16 Feb 2016 

Pulmatrix Inc:Capsugel and Pulmatrix enter collaboration to develop and manufacture novel inhaled therapeutics.Agreement gives capsugel rights to manufacture clinical trial and commercial batches of Isperse(TM)-based inhaled therapeutic candidates.Capsugel will combine spray drying process development, scale-up expertise commercial manufacturing capabilities with pulmatrix's isperse.  Full Article

BRIEF-Pulmatrix posts Q3 net loss of $0.22 per share

* Pulmatrix provides Q3 2017 highlights and Q3 2017 updated financials